Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan L Wright

Showing results (181-190 of 204) with videos related to

Pageof 21
Sort By:
The Journal of Urology|August 27, 2021
Identifying the Optimal Number of Neoadjuvant Chemotherapy Cycles in Patients with Muscle Invasive Bladder CancerDavid D'Andrea, Peter C Black, Homayoun Zargar, et al.
BJU International|November 5, 2020
Neoadjuvant chemotherapy plus radical cystectomy versus radical cystectomy alone in clinical T2 bladder cancer without hydronephrosisFrancesco Soria, Peter C Black, Adrian S Fairey, et al.
Urologic Oncology|September 3, 2025
Agreement between transurethral resection of bladder tumor and radical cystectomy pathology in patients with bladder cancer subtype histology: A retrospective cohort studyDimitra Rafailia Bakaloudi, Elizabeth L Koehne, Jenna M Voutsinas, et al.
Molecular Oncology|August 3, 2023
Pharmacological NF-κB inhibition decreases cisplatin chemoresistance in muscle-invasive bladder cancer and reduces cisplatin-induced toxicitiesRui M Gil da Costa, Christine Levesque, Daniella Bianchi-Frias, et al.
Cancer Research Communications|August 6, 2025
Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted TherapiesHyun Jung Lee, Roman Gulati, Erolcan Sayar, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 15, 2026
Bladder Cancer, Version 1.2026, NCCN Clinical Practice Guidelines In OncologyThomas W Flaig, Philippe E Spiess, Michael Abern, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 6, 2020
Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in OncologyThomas W Flaig, Philippe E Spiess, Neeraj Agarwal, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 16, 2024
NCCN Guidelines® Insights: Bladder Cancer, Version 3.2024Thomas W Flaig, Philippe E Spiess, Michael Abern, et al.
Clinical Genitourinary Cancer|September 6, 2024
Association of Tumor Mutational Burden and Microsatellite Instability With Response and Outcomes in Patients With Urothelial Carcinoma Treated With Immune Checkpoint InhibitorDimitra Rafailia Bakaloudi, Rafee Talukder, Dimitrios Makrakis, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|October 18, 2023
The effect of cisplatin-based neoadjuvant chemotherapy on the renal function of patients undergoing radical cystectomyMatthew D Ho, Anna J Black, Homayoun Zargar, et al.
Pageof 21

Showing results (181-190 of 204) with videos related to

Sort By:
Pageof 21
The Journal of Urology|August 27, 2021
Identifying the Optimal Number of Neoadjuvant Chemotherapy Cycles in Patients with Muscle Invasive Bladder CancerDavid D'Andrea, Peter C Black, Homayoun Zargar, et al.
BJU International|November 5, 2020
Neoadjuvant chemotherapy plus radical cystectomy versus radical cystectomy alone in clinical T2 bladder cancer without hydronephrosisFrancesco Soria, Peter C Black, Adrian S Fairey, et al.
Urologic Oncology|September 3, 2025
Agreement between transurethral resection of bladder tumor and radical cystectomy pathology in patients with bladder cancer subtype histology: A retrospective cohort studyDimitra Rafailia Bakaloudi, Elizabeth L Koehne, Jenna M Voutsinas, et al.
Molecular Oncology|August 3, 2023
Pharmacological NF-κB inhibition decreases cisplatin chemoresistance in muscle-invasive bladder cancer and reduces cisplatin-induced toxicitiesRui M Gil da Costa, Christine Levesque, Daniella Bianchi-Frias, et al.
Cancer Research Communications|August 6, 2025
Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted TherapiesHyun Jung Lee, Roman Gulati, Erolcan Sayar, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 15, 2026
Bladder Cancer, Version 1.2026, NCCN Clinical Practice Guidelines In OncologyThomas W Flaig, Philippe E Spiess, Michael Abern, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 6, 2020
Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in OncologyThomas W Flaig, Philippe E Spiess, Neeraj Agarwal, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 16, 2024
NCCN Guidelines® Insights: Bladder Cancer, Version 3.2024Thomas W Flaig, Philippe E Spiess, Michael Abern, et al.
Clinical Genitourinary Cancer|September 6, 2024
Association of Tumor Mutational Burden and Microsatellite Instability With Response and Outcomes in Patients With Urothelial Carcinoma Treated With Immune Checkpoint InhibitorDimitra Rafailia Bakaloudi, Rafee Talukder, Dimitrios Makrakis, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|October 18, 2023
The effect of cisplatin-based neoadjuvant chemotherapy on the renal function of patients undergoing radical cystectomyMatthew D Ho, Anna J Black, Homayoun Zargar, et al.
Pageof 21